Etoricoxib
As of the edition of 20 October 2026, Etoricoxib is a small molecule: marketed, first approved in 2002 (ES); acts on PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Exxiv
- First approved
- 25 July 2002 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Organon; 3 holders in all
- Registered trials
- 76, 7 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Nervous system; Skin and connective tissue; Inherited and neonatal; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Etoricoxib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGS2 | Prostaglandin G/H synthase 2 | P35354 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 7 | 0 | 0 |
| Phase 1 | 4 | 2 | 0 | 0 |
| Phase 2 | 9 | 5 | 0 | 2 |
| Phase 3 | 32 | 28 | 1 | 1 |
| Phase 4 | 24 | 14 | 1 | 4 |
| All trials | 76 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Applicant and Lead sponsor of trials | 2000 to now |